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Abstract
Background: Giant cell tumors (GCTs) of bone are primary benign bone tumors that are characterized by a high
number of osteoclast-like multinuclear giant cells (MNCs). Recent studies suggest that the spindle-shaped stromal
cells in GCTs are tumor cells, while monocyte-like cells and MNCs are reactive osteoclast precursor cells (OPCs) and
osteoclasts (OCs), respectively. In this study, we investigated the pathogenesis of osteoclastic bone destruction in
GCTs by focusing on the role of the vascular endothelial growth factor (VEGF)-Flt-1 (type-1 VEGF receptor)-focal
adhesion kinase (FAK) pathway.
Methods: The motility of OPCs cells was assessed by a chemotaxis assay and the growth of OPCs was examined
using a cell proliferation assay. The expression of VEGF and activation of Flt-1 and FAK in clinical GCT samples and
in OPCs were detected by immunohistochemistry and immunoblotting. The correlation between the expression
levels of activated Flt-1 and FAK and clinical stages of GCTs was investigated by immunohistochemistry.
Results: In GCT samples, CD68, a marker of OPCs and OCs, co-localized with Flt-1. Conditioned media from GCT
tissue (GCT-CM) enhanced the chemotaxis and proliferation of OPCs. GCT-CM also stimulated FAK activation in
OPCs in vitro. Moreover, there was a correlation between the clinical stage of GCTs and the expression of tyrosine-
phosphorylated Flt-1 and FAK.
Conclusions: Our results suggest that the VEGF-Flt-1-FAK pathway is involved in the pathogenesis of bone
destruction of GCTs.
Background
Giant cell tumors (GCTs) of bone are rare primary ske-
letal neoplasms that occur in young adults [1]. The his-
tological phenotype of GCTs is characterized by a large
number of osteoclast-like giant multi-nuclear cells
(MNCs), which is why this tumor is called an osteoclas-
toma or giant cell tumor. Apart from the MNCs, GCTs
contain two types of mononuclear cells. One cell type
has a round morphology and resembles monocytes
(monocyte-like cells), while the other is a spindle-
shaped, fibroblast-like stromal cell (stromal cells) [2].
Primary cell cultures of GCTs revealed that the stromal
cells are likely the proliferating cell type in GCTs
because the monocyte-like cells and MNCs are lost after
several culture passages [3]. Based on these observations,
the current hypothesis for the cellular origin of GCTs is
that the stromal cells in GCTs are tumor cells, the
monocyte-like cells are reactive macrophages and/or
osteoclast precursor cells (OPCs), and the MNCs are
reactive osteoclasts (OCs) [4].
Recently, it was reported that these stromal cells
secrete several cytokines and differentiation factors,
including TGF-b [5], MCP-1[6], RANKL [7] and M-CSF
[8]. These soluble factors could function as monocyte
chemoattractants and stimulate osteoclast differentia-
tion, suggesting that the stromal cells stimulate blood
monocytes to migrate into the tumor tissue and enhance
in situ osteoclastogenesis, leading to extended osteolysis
by OCs.
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growth factor (VEGF)-Flt-1 (type-1 VEGF receptor)-
focal adhesion kinase (FAK) pathway may be involved in
the chemotaxis and cell proliferation of OPCs and con-
tribute to arthritic joint destruction [9]. VEGF overex-
pression has also been associated with the biological
aggressiveness of GCTs [10]. Therefore, we hypothesized
that the stromal cells in GCTs produce VEGF that
recruits OPCs to the neoplastic lesions. In this study, we
examined clinical GCT samples in order to determine
the possible role of the VEGF-Flt-1-FAK pathway in the
pathogenesis of bone destruction in GCTs.
Methods
Patients and tissue specimens
The Institutional Review Board of Kyushu University
School of Medicine, Fukuoka, Japan approved the proto-
col to obtain and examine surgical GCT specimens.
Twenty-one GCT patients were surgically treated in the
Department of Orthopaedic Surgery, Kyushu University.
All tumor specimens were formalin-fixed and paraffin-
embedded, and 5-mm sections were cut from one repre-
sentative block for molecular analyses.
Agents
Sprague-Dawley rats were purchased from KBT Oriental
(Saga, Japan). Recombinant human VEGF was obtained
from Genzyme/Techne (Minneapolis, MN). Anti-VEGF,
-Flt-1 and -Flk-1 Abs were purchased from Santa Cruz
B i o t e c h n o l o g y( S a n t aC r u z ,C A ) .T h ea n t i - F A KA bw a s
obtained from Upstate Biotechnology (Lake Placid, NY).
Antibodies specific for the phosphotyrosine residue at
position 397 in FAK (pY-FAK Ab) and anti-tyrosine
phosphorylated Flt-1 (pY-Flt-1) were purchased from
Invitrogen (Carlsbad, CA) and Oncogene (San Diego,
CA), respectively. The VEGF receptor tyrosine kinase
(RTK) inhibitor (ZD4190) was purchased from Calbio-
chem (San Diego, CA).
Cell culture
Rat osteoclast precursor cells (rOPCs) were harvested
using by the modified method as previously described
[11](Takeshita S et al. 2000). Briefly, the femurs and
tibias of 1-day-old Sprague-Dawley rats were asepti-
cally resected. The bone ends were cut and the mar-
row cavity was flushed with a-MEM. The marrow cells
were collected, washed and cultured in a-MEM con-
taining 10% FCS and rhM-CSF (100 ng/mL) supple-
mented with 100 U/mL penicillin and 100 mg/mL
streptomycin. After three days of culture, the cells
were vigorously washed to remove the nonadherent
cells, detached by pipetting and subcultured. After cul-
turing for an additional three days, the cells were har-
vested and used as rOPCs.
Immunohistochemistry and immunofluorescence
Immunohistochemistry was performed as previously
described [12]. Surgical specimens were initially decalci-
fied for two weeks in an EDTA-containing buffer and
embedded in paraffin. The endogenous peroxidase activ-
ity was quenched by incubating the sections for an addi-
tional 30 min in absolute methanol and 3% hydrogen
peroxide. The slides were then incubated with the
appropriate primary Abs, followed by biotinylated sec-
ondary Abs and peroxidase-conjugated streptavidin. The
signals were detected using 3-amino-9-ethylcarbazole in
N,N-dimethylformamide. To examine the pY-Flt-1 and
pY-FAK levels in GCT samples, the staining intensity of
each specimen was scored as follows: 1 (weak staining;
less than 10% of cells were positive), 2 (intermediate
staining; 10-50% positive) and 3 (strong staining; >50%
positive). All molecular variables were scored by one
investigator, who was blinded to the clinical stages of
the patients.
For immunofluorescence, the samples were incubated
with the primary Abs overnight at 4°C. The samples
were washed in PBS and then incubated with FITC or
TRITC-conjugated secondary Abs. Then, the sections
were mounted and examined by confocal laser scanning
microscopy.
Tissue culture of giant cell tumors of bone
Primary cultures of GCTs were obtained from surgical
samples of lytic bone lesions. As previously described
[6], fresh tumor tissues were minced in DMEM contain-
ing 10% FBS supplemented with 100 U/mL penicillin
and 100 μg/mL streptomycin. The cell suspension con-
taining small tissue pieces was plated in a 10 cm-culture
dish and incubated at 37°C in a humidified atmosphere
with 5% CO2 and 95% air. Half of the culture medium
was replaced every three days with fresh DMEM con-
taining 10% FBS. When the cells reached confluency,
the primary cultures were scraped and subcultured.
After several passages, the multinucleated giant cells
and monocyte/macrophage-like round cells progressively
disappeared from the cultures and only the proliferating
spindle-shaped cells remained. At passage eight, the
cells were cultured with serum-free DMEM for 24 h
and the conditioned medium was collected, filtered
through 2.5 μm filters, and used as GCT-conditioned
medium (GCT-CM).
Immunoblotting
When the cells reached approximately 70% confluency,
they were harvested and solubilized in lysis buffer [20
mM Tris (pH 7.4), 250 mM NaCl, 1.0% NP40, 1 mM
EDTA, 50 mg/mL leupeptin, and 1 mM phenylmethyl-
sulfonyl fluoride]. The protein quantity was determined
with a Bradford protein assay (Bio-Rad, Hercules, CA).
Matsumoto et al. Journal of Orthopaedic Surgery and Research 2010, 5:85
http://www.josr-online.com/content/5/1/85
Page 2 of 8The samples were separated on 4-12% gradient pre-cast
MOPS-polyacrylamide gels (Novex, San Diego, CA) and
blotted onto nitrocellulose filters. After transfer, the fil-
ters were pre-treated with TBS containing 5% dry milk
and 0.05% Triton X for 2 h at room temperature and
then incubated with the indicated primary antibodies for
2 h at room temperature. After several washes, the
membranes were probed with the appropriate horserad-
ish peroxidase-conjugated secondary Abs at room
temperature for 1 h. After the final wash, the immunor-
eactivity of the blots was detected using an enhanced
chemiluminescence system (Amersham, Arlington
Heights, IL).
Enzyme-linked immunosorbent assay (ELISA) for VEGF
The VEGF levels in GCT-CM were determined using an
ELISA kit from R&D Systems (Minneapolis, MN).
Cell proliferation assay
rOPCs cells seeded in culture plates were incubated in
serum-free media with various reagents (GCT-CM,
VEGF and ZD4190) for 24 h. The cell growth rate was
determined using a Celltiter-Glo Luminescent Cell Via-
bility Assay Kit (Promega, Madison, WI) according to
the manufacturer’s protocol.
Chemotaxis assay
The chemotaxis assay was performed using transwell
chambers (Costar, Cambridge, MA) as previously
described [13-15]. Briefly, rOPCs were suspended in
serum-free a-MEM containing 1% bovine serum albumin
and seeded in the upper chamber. The lower chamber
was filled with serum-free a-MEM supplemented with or
without various cytokines. Polyvinylpyrrolidone-free
polycarbonate filters with 8.0-μm pores were coated with
type IV collagen and inserted between the two chambers.
Then, the cells were allowed to migrate for 6 h at 37°C.
After this incubation period, the cells that had migrated
to the lower side of the filter were fixed, stained and
counted using five fields/filter under a microscope.
Statistical analysis
The results obtained from the chemotaxis and cell prolif-
eration assays are expressed as the means ± SD and were
statistically analyzed by the Student’s t-test. The associa-
tion between the expression levels of various molecular
factors (pY-FAK and pY-Flt-1) and the clinical stages
were analyzed using the Mann-Whitney U test.
Results
Immunolocalization of VEGF, Flt-1 and Flk-1 in GCT
samples
We initially analyzed the expression profiles of VEGF
and the VEGF receptors in GCT specimens. TRAP
staining demonstrated the presence of bone-resorbing
OCs (data not shown). To determine the immunolocali-
zation of VEGF and the VEGF receptors in GCT speci-
mens, we performed immunohistochemistry using serial
sections of GCT samples. VEGF expression was
observed in all of the stromal cells (arrows), monocyte-
like cells (arrowheads) and MNCs (asterisks)(Figure 1a).
Flt-1 was expressed in MNCs (asterisks) and a portion
of the mononuclear cells that were identified as mono-
cyte-like cells (arrowheads) (Figure 1b). However, Flk-1
expression was not clearly detected in the specimens
(Figure 1c). Tissue sections stained with preimmune
control IgG showed no specific staining (Figure 1d).
These results suggest that Flt-1, but not Flk-1, plays a
principal role in VEGF signaling in GCTs.
Co-localization of CD68 and Flt-1 in monocyte-like cells
and MNCs at the site of bone destruction
Because monocyte-like cells and MNCs in GCTs express
CD68 [16], we investigated whether Flt-1 co-localized
with CD68-positive cells in GCT samples. The speci-
mens were incubated with anti-CD68 (Figure 2a and 2d)
and anti-Flt-1 (Figure 2b and 2e) Abs, followed by
TRITC- or FITC-labeled secondary Abs, respectively. As
shown in Figure 2c and 2f, CD68 and Flt-1 co-localized
in monocyte-like cells (arrows) and MNCs (arrowheads)
in these specimens. These results suggest that MNCs
and monocyte-like cells (thought to be OCs and OPCs,
respectively) in the GCT samples expressed Flt-1, indi-
cating that the VEGF-Flt-1 pathway plays specific roles
in osteoclastic bone destruction in GCTs.
Conditioned media from GCT cultures (GCT-CM) enhanced
chemotaxis and proliferation of OPCs via VEGF signaling
Next, we attempted to elucidate whether VEGF-signal-
ing is involved in recruiting CD68-positive cells, such as
OPCs, in GCTs. We investigated the effects of GCT-
CM on the biological phenotypes of OPCs. To examine
the VEGF protein in GCT-CM, we used a VEGF-ELISA,
and confirmed that the VEGF concentration in GCT-
CM was approximately 2.8 ng/mL. We previously
showed that VEGF treatment stimulates the tyrosine
phosphorylation of Flt-1 in RAW cells, a model of
OPCs [9]. In this study, we used OPCs derived from rat
bone marrow cells (rOPCs) [17]. We previously reported
that VEGF stimulated the interaction between tyrosine
phosphorylated Flt-1 (pY-Flt-1) and FAK, resulting in
the autophosphorylation of the tyrosine residue at posi-
tion 397 in FAK (pY-FAK) in RAW cells. We thus
investigated the effects of GCT-CM on pY-FAK in
rOPCs and found that GCT-CM increased pY-FAK
expression and that this effect was inhibited by ZD4190
treatment (Figure 3). Since we previously reported that
VEGF stimulated the chemotaxis and proliferation of
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on the chemotaxis and proliferation of rOPCs. GCT-
CM enhanced the chemotaxis and proliferation of
rOPCs to levels that were comparable to VEGF stimula-
tion, and the addition of ZD4190 to the GCT-CM inhib-
ited these effects (Figure 4a and 4b). These results
suggest that GCT-CM enhanced the chemotaxis and
cell proliferation of OPCs via VEGF-Flt-1-FAK signaling.
Possible involvement of the VEGF-Flt-1-FAK pathway in
the bone destruction of GCTs
Immunohistochemical analyses showed that pY-Flt-1
was expressed in monocyte-like cells and MNCs (Figure
5a) and that pY-FAK was expressed in monocyte-like
cells in GCT specimens (Figure 5b). These results sug-
gest that VEGF binding to its receptor, Flt-1, on mono-
cyte-like cells may induce the tyrosine phosphorylation
of FAK in cells within GCTs.
Correlation between the clinical stage and pY-Flt-1 and
pY-FAK expression in GCTs
To determine the biological significance of VEGF-Flt-1-
FAK signaling in GCTs, we examined the correlation
between the expression levels of pY-Flt-1 and pY-FAK
and the clinical stages of GCTs. Based on plain X-ray
films at the time of presentation, 11 cases were clinically
graded as stage II GCTs, eight cases as stage III, and
only two cases as stage I. Immunohistochemical analysis
showed that the pY-Flt-1 and pY-FAK expression levels
in stage I-II GCTs were significantly lower than those in
stage III GCTs (p < 0.05) (Figure 6a and 6b).
Discussion
The association between VEGF expression and angio-
genesis has been detected in many solid tumors. In
addition, VEGF-induced vascularization during bone
development is critical for the formation of OCs [18,19].
Figure 1 Expression of VEGF and the VEGF receptors in giant cell tumors (GCTs) of bone. Surgical specimens were fixed in formalin and
serially sectioned. (a) VEGF was expressed in stromal cells (arrows), monocyte-like cells (arrowheads) and multinuclear cells (MNCs) (asterisks). (b)
Flt-1 expression was mainly detected in monocyte-like cells (arrowheads) and MNCs (asterisks). (c) Flk-1 expression was not clearly detected in
the serial sections. (d) Tissue sections stained with preimmune control IgG showed no specific staining. Original magnification: X 200. Scale bar:
50 μm.
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and osteoclastogenesis. It has been reported that the
level of VEGF gene expression in GCTs correlates with
the clinical stage at presentation defined by Enneking’s
surgical staging system [10], suggesting that the produc-
tion of VEGF by tumor cells and the induction of
angiogenesis may partially contribute to tumor progres-
sion. In this study, VEGF was clearly expressed in stro-
mal cells, monocyte-like cells and MNCs in GCTs.
CD68, an intracellular glycoprotein, was expressed in
monocyte lineage cells, including OPCs and OCs [20].
Therefore, it is possible that the infiltrating MNCs and
monocyte-like cells in GCTs mature into OCs and
OPCs, respectively. In contrast, the stromal cells did not
express CD68, suggesting that they did not originate
from the monocyte-macrophage lineage.
In endothelial cells, the VEGF signals were mainly
mediated via Flk-1, the type-II VEGF receptor [21].
However, in monocytic lineage cells, most VEGF signals
were transmitted via Flt-1, as was previously shown [9].
In regard to the effect of VEGF on monocytes migra-
tion, VEGF stimulated the chemotaxis of human mono-
cytes corresponding to the previous report [22].
(Control; 5 ± 1 cells, 10 nM VEGF: 50 ± 5 cells, 10 nM
MCP-1: 99 ± 3 cells) We also found that VEGF treat-
ment induced the tyrosine phosphorylation of FAK (pY-
FAK). In this study, we first demonstrated that CD68
and Flt-1 co-localized in MNCs and monocyte-like cells,
which are thought to be OPCs in GCTs. However, these
cells did not express Flk-1. We also indicated that these
Figure 2 Co-localization of CD68 and Flt-1 in GCTs. The sections were prepared as described in Fig. 1 and stained with anti-CD68 (a and d)
and anti-Flt-1 (b and e) Abs, followed by TRITC- and FITC-conjugated secondary Abs, respectively. The images were merged (c and f). Arrows
indicate monocyte-like cells (a-c) and arrowheads indicate MNCs (d-f). Scale bar: 10 μm.
Figure 3 Effect of GCT-CM on FAK phosphorylation in rat
osteoclast precursor cells (rOPCs). rOPCs were harvested and
cultured in a serum-free medium overnight. Then, the cells were
washed and incubated for 5 min in the presence of various
reagents (GCT-CM, VEGF and ZD4190). The samples were
immunoblotted with anti-tyrosine phosphorylated FAK (anti-pY-FAK)
or anti-FAK Abs.
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Flt-1 (pY-Flt-1) as shown in Figure 5. In addition, pY-
FAK was expressed in monocyte-like cells in GCT surgi-
cal specimens. These results support the hypothesis that
VEGF is released from stromal cells, pOCs and OCs.
Then, through paracrine and autocrine mechanisms, the
secreted VEGF activates the VEGF-Flt-1-FAK pathway.
The activation of this signaling pathway might be
involved in the migration of these cells into the lesion at
the site of bone destruction in GCTs.
We recently showed that VEGF stimulates the chemo-
taxis and cell proliferation of RAW cells, a model of
mouse OPCs. Thus, we investigated the biological
e f f e c t so fV E G Fi nG C T su s i n gG C T - C Ma n dr O P C s .
Consistent with the immunohistochemistry results,
GCT-CM contained VEGF and treating rOPCs with
GCT-CM resulted in the tyrosine phosphorylation of
FAK within cells. GCT-CM also stimulated the chemo-
taxis and proliferation of rOPCs. All of these GCT-CM-
induced effects were inhibited by adding ZD4190, a
VEGF RTK inhibitor, to the GCT-CM. It was recently
reported that VEGF treatment induces the formation of
Figure 4 Effect of GCT-CM on the chemotaxis and proliferation
of rat osteoclast precursor cells (rOPCs). (a) rOPCs were cultured
in serum-free medium overnight and washed twice with PBS. The
cells were added to the upper compartment of a modified Boyden
chamber. GCT-CM and VEGF (10 ng/mL) with or without ZD4190
were added to the lower compartments, and the chambers were
incubated for 6 h at 37°C. The migrated cells were stained and
counted as described in the Materials and Methods. The results are
shown as the means ± SD of two independent experiments that
were performed triplicate (* p < 0.01). (b) rOPCs in a 96-well plate
were cultured in a serum-free medium for 24 h and washed with
PBS. Then, the cells were stimulated with VEGF and GCT-CM with or
without ZD4190 for 24 h. Cellular proliferation was assessed by the
Celltiter-Glo Luminescent Cell Viability Assay. Results show the
means ± SD of two independent experiments that were performed
in triplicate. (* p < 0.01).
Figure 5 Expression of pY-Flt-1 and pY-FAK in GCTs.T h e
sections were prepared as described in Fig. 1 and stained with anti-
pY-Flt-1 (a) and anti-pY-FAK (b) Abs. (a) pY-Flt-1 expression was
detected in monocyte-like cells (arrows) and MNCs (asterisks). (b)
pY-FAK expression was mainly detected in monocyte-like cells
(arrows) but not MNCs (asterisks). Original magnification: X 200.
Scale bar: 50 μm.
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tional macrophage colony-stimulating factor [23]. Thus,
it is possible that the VEGF produced by GCTs directly
stimulates the formation of MNCs within the tumor.
These results suggest that the effects of GCT-CM,
including the stimulation of chemotaxis and prolifera-
tion of rOPCs but not osteoclastogenesis, were partially
dependent on VEGF-Flt-1-FAK signaling and that this
signaling plays important roles in recruiting OPCs into
the GCT tissue. On the other hand, ZD4190 did not
completely block the basal level of chemotaxis and pro-
liferation of rOPCs. Therefore, we assumed that many
other cytokines, including TGF-b1[5], MCP-1[6] and M-
CSF, in GCTs influence the chemotaxis and growth of
rOPCs. Meanwhile, a recent study showed that GCTs
enhanced osteoclastogenesis via paracrine VEGF secre-
tion under local hypoxic conditions and indicated that
this might be a critical mechanism for the pathogenesis
of GCTs [24]. However, when we harvested GCT-CM
under normoxia, GCT-CM did not enhance the osteo-
clastogenesis of OPCs. Therefore, the role of VEGF in
osteoclastogenesis in GCTs in vivo should be further
investigated.
To assess the pathological significance of the VEGF-
Flt-1-FAK pathway, we also examined the correlation
between the pY-Flt-1 and pY-FAK expression levels and
the clinical stage of GCTs at presentation. The biologi-
cal aggressiveness of the tumors was classified as pre-
viously described [25]. In the present study, we
demonstrated that the pY-Flt-1 and pY-FAK expression
levels correlated with clinical stage of the tumor.
A relatively high level of pY-Flt-1 and pY-FAK expression
was observed in stage III GCTs compared with stages I-II
GCTs. Although a larger number of tumors are needed
to confirm these clinical correlations, our results suggest
that activation of the VEGF-Flt-1-FAK pathway may con-
tribute to the clinical progression of GCTs.
Conclusions
In conclusion, our results suggest that the VEGF-Flt-1-
FAK pathway is potentially involved in recruiting OPCs
in GCTs. This pathway, in concert with other factors
such as TGF-b and MCP-1, may stimulate the recruit-
ment and cell proliferation of OPCs into GCTs, result-
ing in tumor progression. In this study, ZD4190, a p.o.-
active VEGF RTK inhibitor, disrupted VEGF signaling
mediated by Flt-1 as well as Flk-1, indicating that
ZD4190 administration may simultaneously inhibit
VEGF-induced angiogenesis and the recruitment and
proliferation of OPCs in GCTs. Therefore, it is concei-
vable that VEGF RTK inhibitors may be a useful clinical
therapeutic for GCTs.
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